NCT00641927

Brief Summary

This study examines the relative safety and benefit of antidepressant therapy (versus recommended mood stabilizer therapy)of bipolar type II major depressive episode. We hypothesize that antidepressant therapy will be superior to mood stabilizer therapy with little or no difference in treatment emergent manic symptoms.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Apr 2002

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2002

Completed
4.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2006

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2006

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

March 18, 2008

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 24, 2008

Completed
Last Updated

March 24, 2008

Status Verified

March 1, 2008

Enrollment Period

4.5 years

First QC Date

March 18, 2008

Last Update Submit

March 18, 2008

Conditions

Keywords

bipolar disorderbipolar type II disorderantidepressantmood stabilizervenlafaxinelithium carbonate

Outcome Measures

Primary Outcomes (1)

  • Reduction in Hamilton Depression Rating Scale score.

    12 Weeks

Secondary Outcomes (1)

  • Change in Young Mania Rating Scale score.

    12 Weeks

Study Arms (2)

1

EXPERIMENTAL

Antidepressant

Drug: Venlafaxine

2

ACTIVE COMPARATOR

Drug

Drug: Lithium Carbonate

Interventions

37.5 mg - 375 mg daily, 12 Weeks

Also known as: Effexor-XR
1

300 mg - 2100 mg daily, 12 weeks

Also known as: Lithium
2

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • men and women (all races and ethnicity) greater than or equal to18 years of age,
  • DSM IV diagnosis of BP II disorder,
  • Current DSM IV MDE,
  • HAM-D17 score greater than or equal to 16,
  • Drug free from prior psychotropic medication greater than or equal to 7 days (2 weeks for MAOIs)

You may not qualify if:

  • History of mania,
  • Other primary DSM IV Axis I diagnosis,
  • Alcohol or drug dependence within 3 months,
  • History of nonresponse to Effexor-XR or lithium in the present MDE,
  • History of allergic reaction to Effexor-XR or lithium,
  • Medical contraindications to treatment with Effexor-XR or lithium,
  • Unstable medical condition,
  • Pregnant or breast-feeding women,
  • Women of child-bearing potential not using a medically approved form of contraception,
  • Actively suicidal or requiring hospitalization,
  • Requiring concurrent antidepressant, neuroleptic or mood stabilizer therapy,
  • Prior investigational study within 4 weeks of starting active therapy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Depression Research Unit, Department of Psychiatry, University of Pennsylvania

Philadelphia, Pennsylvania, 19104-3309, United States

Location

Related Publications (1)

  • Shults J, Sun W, Tu X, Kim H, Amsterdam J, Hilbe JM, Ten-Have T. A comparison of several approaches for choosing between working correlation structures in generalized estimating equation analysis of longitudinal binary data. Stat Med. 2009 Aug 15;28(18):2338-55. doi: 10.1002/sim.3622.

MeSH Terms

Conditions

Bipolar Disorder

Interventions

Venlafaxine HydrochlorideLithium CarbonateLithium

Condition Hierarchy (Ancestors)

Bipolar and Related DisordersMood DisordersMental Disorders

Intervention Hierarchy (Ancestors)

CyclohexanolsHexanolsFatty AlcoholsAlcoholsOrganic ChemicalsPhenethylaminesEthylaminesAminesCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsLipidsCarbonatesAlkaliesInorganic ChemicalsCarbonic AcidCarbon Compounds, InorganicLithium CompoundsMetals, AlkaliElementsMetals, LightMetals

Study Officials

  • Jay D Amsterdam, MD

    Depression Research Unit, School of Psychiatry, University of Pennsylvania

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

March 18, 2008

First Posted

March 24, 2008

Study Start

April 1, 2002

Primary Completion

October 1, 2006

Study Completion

October 1, 2006

Last Updated

March 24, 2008

Record last verified: 2008-03

Locations